Home » 2019
Yearly Archives: 2019
Journal Club – October 24th, 2019
Please join us for the next Journal Club scheduled for October 24th, 2019 when the following articles will be presented.
Nicole Jawitz, MD will discuss the IBD article:
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
N Engl J Med. 2019 Sep 26;381(13):1201-1214. PDF. PMID: 31553833.
Authors of this trial evaluated ustekinumab as 8-week induction therapy and 44-week maintenance therapy in patients with moderate-to-severe ulcerative colitis.
Zachary Spiritos, MD will discuss the Hepatology article:
Identifying optimal candidates for early TIPS among patients with cirrhosis and acute variceal bleeding: a multicentre observational study.
Gut 2019;68:1297–1310. PDF PMID:30415233
Authors performed this large, multicentre, observational study to assess the effects of early TIPS (compared with standard treatment) on the mortality, failure to control acute bleeding or rebleeding, new or worsening ascites and overt hepatic encephalopathy (OHE) among patients with cirrhosis and AVB who were stratified by current available risk stratification systems.
Jose Ruiz, MD will discuss the “Hot Topic” article:
Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn
N Engl J Med 2019; 381:1513-1523. PDF PMID: 31618539
Authors performed a randomized trial of medical therapy vs surgical therapy for patients with PPI-refractory heartburn symptoms.
Journal Club – September 26, 2019
Please join us for the first Journal Club Session of the year in which the following articles will be discussed:
Brendon O’Connell, MD will present the article, “Timeline and location of recurrence following successful ablation in Barrett’s oesophagus: an international multicentre study.”
PMID: 30635408. Gut. 2019 Aug;68(8):1379-1385. doi: 10.1136/gutjnl-2018-317513.
Surveillance interval protocols after complete remission of intestinal metaplasia (CRIM) post radiofrequency ablation (RFA) in Barrett’s esophagus (BE) are currently empiric and not based on substantial evidence. This study aimed to assess the timeline, location and patterns of recurrence following CRIM to inform these guidelines.
Farah Hussain, MD will present the article, Endoscopic scar assessment after colorectal endoscopic mucosal resection scars: when is biopsy necessary (EMR Scar Assessment Project for Endoscope (ESCAPE) trial).
PMID: 30635409. Gut. 2019 Sep;68(9):1633-1641. doi: 10.1136/gutjnl-2018-316574.
It is unclear whether endoscopic assessment of scars after colorectal endoscopic mucosal resection (EMR) has to include biopsies, even if endoscopy is negative. Vice versa, endoscopic diagnosis of recurrent adenoma may not require biopsy before endoscopic reinterventions. This study prospectively analyzed various endoscopic modalities in the diagnosis of recurrence following EMR.
Shai Posner, MD will present the article, “Hemostatic spray powder TC-325 for GI bleeding in a nationwide study: survival and predictors of failure via competing risks analysis.”
PMID: 31220444. Gastrointest Endosc 2019;90:581-90. doi: 10.1016/j.gie.2019.06.008.
TC-325 (Hemospray) is an inorganic hemostatic powder recently approved by the U.S. Food and Drug Administration. This study aimed to examine the effectiveness, safety, and predictors of TC-325 failure in a large real-life cohort.
